BN Business News
Add your company to Business Communicator →

Business · 13/02/2026Updated: 10/16/2026 · 1 min read

Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases

Summary

The National Cancer Institute is considering granting an Exclusive Patent License to Kyverna Therapeutics, Inc. for the treatment or prevention of B Cell Mediated Autoimmune Diseases.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →